Allergy

Article	Citations
Risk factors for severe and critically ill COVID‐19 patients: A review	974
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria	516
EAACI guidelines: Anaphylaxis (2021 update)	253
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update	196
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease	181
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice	155
The role of allergen‐specific IgE, IgG and IgA in allergic disease	140
Advances and highlights in allergic rhinitis	119
Interleukin‐31: The “itchy” cytokine in inflammation and therapy	113
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches	112
Abstracts Poster	112
Advances and highlights in biomarkers of allergic diseases	107
Spotlight on microRNAs in allergy and asthma	103
Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?	102
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID‐19 vaccines	91
Advances and highlights in asthma in 2021	90
Biologics and airway remodeling in severe asthma	90
Allergenic components of the mRNA‐1273 vaccine for COVID‐19: Possible involvement of polyethylene glycol and IgG‐mediated complement activation	90
The global burden of illness of peanut allergy: A comprehensive literature review	90
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines	86
The ingenious mast cell: Contemporary insights into mast cell behavior and function	85
Regulatory B cells, A to Z	84
Predictors of treatment response in chronic spontaneous urticaria	83
Butyrate as a bioactive human milk protective component against food allergy	83
Roles of follicular helper and regulatory T cells in allergic diseases and allergen immunotherapy	81

Frequency of food allergy in Europe: An updated systematic review and meta‐analysis	81
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 201	80
Climate change and global health: A call to more research and more action	77
Risk factors for severe reactions in food allergy: Rapid evidence review with meta‐analysis	76
Advances and novel developments in mechanisms of allergic inflammation	73
Immunological imprint of COVID‐19 on human peripheral blood leukocyte populations	73
Allergen immunotherapy and/or biologicals for IgE‐mediated food allergy: A systematic review and meta‐analysis	73
Considerations on biologicals for patients with allergic disease in times of the COVID‐19 pandemic: An EAACI statement	72
Phase 2a randomized clinical trial of dupilumab (anti‐IL‐4Rα) for alopecia areata patients	71
Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity	70
Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives	69
Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis	69
Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation	68
Update on pathomechanisms and treatments in allergic rhinitis	65
Profound dysregulation of T cell homeostasis and function in patients with severe COVID‐19	64
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper	64
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma	64
In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion	63
Elastase and exacerbation of neutrophil innate immunity are involved in multi‐visceral manifestations of COVID‐19	63
Cold urticaria – What we know and what we do not know	63
World Health Organization global air quality guideline recommendations: Executive summary	62
The maternal diet index in pregnancy is associated with offspring allergic diseases: the Healthy Start study	60
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status	59
Abstracts	59
Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper	59
Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort	58
Allergies and COVID‐19 vaccines: An ENDA/EAACI Position paper	57
Anaphylaxis to the first dose of mRNA SARS‐CoV‐2 vaccines: Don't give up on the second dose!	57
Hypersensitivity reactions to chemotherapy: an EAACI Position Paper	56
The global impact of the COVID‐19 pandemic on the management and course of chronic urticaria	56
Role of dietary fiber in promoting immune health—An EAACI position paper	56
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis	55
Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances	55
ARIA‐EAACI statement on severe allergic reactions to COVID‐19 vaccines – An EAACI‐ARIA Position Paper	55
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled pha	53
Neutralization of SARS‐CoV‐2 requires antibodies against conformational receptor‐binding domain epitopes	52
Early intervention and prevention of allergic diseases	52
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes	52
The diagnosis and management of allergic reactions in patients sensitized to non‐specific lipid transfer proteins	52
Dexamethasone, pro‐resolving lipid mediators and resolution of inflammation in COVID‐19	52
Eczema herpeticum in atopic dermatitis	51
Single‐cell molecular profiling provides a high‐resolution map of basophil and mast cell development	50
Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria	49
Ragweed plants grown under elevated CO2 levels produce pollen which elicit stronger allergic lung inflammation	49
Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps	49
Accurate and reproducible diagnosis of peanut allergy using epitope mapping	48
EAACI guidelines on the diagnosis of IgE‐mediated food allergy	48
Basophils and their effector molecules in allergic disorders	47
Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy	47
Recent developments in the immunopathology of COVID‐19	47

Allergens and their associated small molecule ligands—their dual role in sensitization	46
Allergen immunotherapy: The growing role of observational and randomized trial “Real‐World Evidence”	46
Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study	46
Detergent exposure induces epithelial barrier dysfunction and eosinophilic inflammation in the esophagus	46
Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions	46
Carbohydrate epitopes currently recognized as targets for IgE antibodies	45
Food allergy, mechanisms, diagnosis and treatment: Innovation through a multi‐targeted approach	45
Emollients in infancy to prevent atopic dermatitis: A systematic review and meta‐analysis	45
The role of CD23 in the regulation of allergic responses	44
Early initiation of short‐term emollient use for the prevention of atopic dermatitis in high‐risk infants—The STOP‐AD randomised controlled trial	44
Mast cell activation is associated with post‐acute COVID‐19 syndrome	44
Asthma phenotypes, associated comorbidities, and long‐term symptoms in COVID‐19	44
Breastfeeding promotes early neonatal regulatory T‐cell expansion and immune tolerance of non‐inherited maternal antigens	44
Biologicals in atopic disease in pregnancy: An EAACI position paper	43
Nutrient supplementation for prevention of viral respiratory tract infections in healthy subjects: A systematic review and meta‐analysis	43
Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID	42
Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I	42
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real‐life study (DUPIREAL)	42
Skin tests in urticaria/angioedema and flushing to Pfizer‐BioNTech SARS‐CoV‐2 vaccine: Limits of intradermal testing	41
One hundred and ten years of Allergen Immunotherapy: A journey from empiric observation to evidence	41
Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study	41
Immunological resilience and biodiversity for prevention of allergic diseases and asthma	40
Basophil activation test shows high accuracy in the diagnosis of peanut and tree nut allergy: The Markers of Nut Allergy Study	40
Infant gut microbiome is enriched with Bifidobacterium longumssp. infantis in Old Order Mennonites with traditional farming lifestyle	39
Electrical impedance spectroscopy for the characterization of skin barrier in atopic dermatitis	39
From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases	39
Glucagon‐like peptide‐1 receptor agonist inhibits aeroallergen‐induced activation of ILC2 and neutrophilic airway inflammation in obese mice	39
Skin biomarkers predict development of atopic dermatitis in infancy	38
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization	38
Butyrate and propionate restore interleukin 13‐compromised esophageal epithelial barrier function	38
Hypersensitivity pneumonitis: Current concepts in pathogenesis, diagnosis, and treatment	37
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection	37
Biology and dynamics of B cells in the context of IgE‐mediated food allergy	37
Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma	37
Epithelial barrier dysfunction in ocular allergy	37
Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment	37
Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease	37
Peanut‐induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry	37
Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis	37
Autoantibodies in COVID‐19 correlate with antiviral humoral responses and distinct immune signatures	36
Allergen‐specific immunotherapy induces the suppressive secretoglobin 1A1 in cells of the lower airways	36
Development and validation of combined symptom‐medication scores for allergic rhinitis*	36
A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2	35
T‐cell subsets in the skin and their role in inflammatory skin disorders	35
Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA	35
Allergen immunotherapy for asthma prevention: A systematic review and meta‐analysis of randomized and non‐randomized controlled studies	35
Climate change: A call to action for the United Nations	34
Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper	34
Molecular allergology and its impact in specific allergy diagnosis and therapy	34
Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis	34
Cashew oral immunotherapy for desensitizing cashew‐pistachio allergy (NUT CRACKER study)	33
Protease allergens as initiators–regulators of allergic inflammation	33
Newly defined allergens in the WHO/IUIS Allergen Nomenclature Database during 01/2019‐03/2021	33
Dupilumab has a profound effect on specific‐IgE levels of several food allergens in atopic dermatitis patients	33
Eosinophils from A to Z	32
Impaired skin barrier and allergic sensitization in early infancy	32
Omics technologies in allergy and asthma research: An EAACI position paper	32
Prevalence and early‐life risk factors of school‐age allergic multimorbidity: The EuroPrevall‐iFAAM birth cohort	32
Single low‐dose exposure to cow’s milk at diagnosis accelerates cow’s milk allergic infants’ progress on a milk ladder programme	31
Prevalence estimates of eight big food allergies in Europe: Updated systematic review and meta‐analysis	31
IL‐37 regulates allergic inflammation by counterbalancing pro‐inflammatory IL‐1 and IL‐33	31
Sounding the alarmins—The role of alarmin cytokines in asthma	31
Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses	31
Mast cell‐derived serotonin enhances methacholine‐induced airway hyperresponsiveness in house dust mite‐induced experimental asthma	31
Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis	31
T‐cell recovery and evidence of persistent immune activation 12 months after severe COVID‐19	31
Hypersensitivity reactions to biologicals: An EAACI position paper	31
Highlights in the advances of chronic rhinosinusitis	30
Exiting the Anthropocene: Achieving personal and planetary health in the 21st century	30
Assessment of biomarkers in pediatric atopic dermatitis by tape strips and skin biopsies	30
Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper	30
Regulatory roles of three miRNAs on allergen mRNA expression in Tyrophagus putrescentiae	30
β‐blockers and ACE inhibitors are not a risk factor for severe systemic sting reactions and adverse events during venom immunotherapy	30
Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study	30
Laundry detergents and surfactants‐induced eosinophilic airway inflammation by increasing IL‐33 expression and activating ILC2s	29
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial	29
Accuracy of serological testing for SARS‐CoV‐2 antibodies: First results of a large mixed‐method evaluation study	29
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study	29
IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases	29
Management of patients with atopic dermatitis undergoing systemic therapy during COVID‐19 pandemic in Italy: Data from the DA‐COVID‐19 registry	29

Secretoglobins in the big picture of immunoregulation in airway diseases	29
Decoding the genetic and epigenetic basis of asthma	29
Sweet syndrome induced by SARS‐CoV‐2 Pfizer‐BioNTech mRNA vaccine	29
Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort‐19 study	29
The important role of non‐covalent drug‐protein interactions in drug hypersensitivity reactions	28
Evolution and long‐term outcomes of combined immunodeficiency due to CARMIL2 deficiency	28
The impact of type 2 immunity and allergic diseases in atherosclerosis	28
Translation and emerging functions of non‐coding RNAs in inflammation and immunity	28
Systemic allergic reactions induced by labile plant‐food allergens: Seeking potential cofactors. A multicenter study	28
Single‐cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis	28
Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis	28
Predicting the recurrence of chronic rhinosinusitis with nasal polyps using nasal microbiota	28
Serum exosome inflamma‐miRs are surrogate biomarkers for asthma phenotype and severity	28
Long‐acting muscarinic antagonists and small airways in asthma: Which link?	28
Children of Asian ethnicity in Australia have higher risk of food allergy and early‐onset eczema than those in Singapore	27
Cannabis‐related allergies: An international overview and consensus recommendations	27
Noninvasive biomarkers identify eosinophilic esophagitis: A prospective longitudinal study in children	27
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA2LEN consensus	27
Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response	27
Distinct expression of SARS‐CoV‐2 receptor ACE2 correlates with endotypes of chronic rhinosinusitis with nasal polyps	27
EAACI Biologicals Guidelines—dupilumab for children and adults with moderate‐to‐severe atopic dermatitis	27
Interleukin‐6: A novel biomarker for monoclonal antibody and chemotherapy‐associated hypersensitivity confirms a cytokine release syndrome phenotype‐endotype association	27
Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines	27
EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old	27
Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum	26
The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine	26
A bird's eye view on the role of dendritic cells in SARS‐CoV‐2 infection: Perspectives for immune‐based vaccines	26
The NLRP3 inflammasome inhibitor, OLT1177®, ameliorates experimental allergic asthma in mice	26
Molecular sensitization patterns in animal allergy: Relationship with clinical relevance and pet ownership	26
Immune modulation via T regulatory cell enhancement: Disease‐modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task	25
Development and validation of the food allergy severity score	25
Gibberellin‐regulated protein sensitization in Japanese cedar (Cryptomeria japonica) pollen allergic Japanese cohorts	25
Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID‐exacerbated respiratory disease	25
COVID‐19 vaccine anaphylaxis: IgE, complement or what else? A reply to: “COVID‐19 vaccine anaphylaxis: PEG or not?”	25
Abstract	25
Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK‐air® real‐world data	25
Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies	25
Monkeypox outbreak in Europe, UK, North America, and Australia: A changing trend of a zoonotic disease	25
Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata	25
Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper	25
European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis	25
CD8+ tissue‐resident memory T cells recruit neutrophils that are essential for flare‐ups in contact dermatitis	25
Association between ambient air pollution and development and persistence of atopic and non‐atopic eczema in a cohort of adults	25
COVID‐19 pandemic and allergen immunotherapy—an EAACI survey	25
A molecular sensitization map of European children reveals exposome‐ and climate‐dependent sensitization profiles	25
Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A cross‐sectional multi‐center study	24
The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID‐19 vaccines	24
Risk factors for systemic reactions in typical cold urticaria: Results from the COLD‐CE study	24
Technical standards in allergen exposure chambers worldwide – an EAACI Task Force Report	24
Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis	24
Association between asthma and clinical mortality/morbidity in COVID‐19 patients using clinical epidemiologic data from Korean Disease Control and Prevention	24
Fatal and near‐fatal anaphylaxis: The Allergy‐Vigilance® Network data (2002–2020)	24
EAACI guidelines on environmental science in allergic diseases and asthma – Leveraging artificial intelligence and machine learning to develop a causality model in exposomics	24
Prenatal antibiotic exposure, asthma, and the atopic march: A systematic review and meta‐analysis	24
Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses	24
The bile acid‐activated retinoic acid response in dendritic cells is involved in food allergen sensitization	24
Mast cell‐pain connection in eosinophilic esophagitis	24
Health effects of exposure to chlorination by‐products in swimming pools	24
Predicting probability of tolerating discrete amounts of peanut protein in allergic children using epitope‐specific IgE antibody profiling	23
TFEB signaling attenuates NLRP3‐driven inflammatory responses in severe asthma	23
Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID‐19 patients	23
Staphylococcus aureus causes aberrant epidermal lipid composition and skin barrier dysfunction	23
National trends in the prevalence of allergic diseases among Korean adolescents before and during COVID‐19, 2009–2021: A serial analysis of the national representative study	23
The skin microbiome in the first year of life and its association with atopic dermatitis	23
Phase 2, randomized multi oral immunotherapy with omalizumab ‘real life’ study	23
Oral desensitization therapy for peanut allergy induces dynamic changes in peanut‐specific immune responses	23
Single‐dose prolonged drug provocation test, without previous skin testing, is safe for diagnosing children with mild non‐immediate reactions to beta‐lactams	23
Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction	23
An exhausted phenotype of TH2 cells is primed by allergen exposure, but not reinforced by allergen‐specific immunotherapy	23
Fungal exposome, human health, and unmet needs: A 2022 update with special focus on allergy	22
COVID‐19 vaccine anaphylaxis: PEG or not?	22
Innate lymphoid cells: The missing part of a puzzle in food allergy	22
Functional iron‐deficiency in women with allergic rhinitis is associated with symptoms after nasal provocation and lack of iron‐sequestering microbes	22
Understanding uncontrolled severe allergic asthma by integration of omic and clinical data	22
Age of onset defines two distinct profiles of atopic dermatitis in adults	22
Safety of combining biologics in severe asthma: Asthma‐related and unrelated combinations	22
Efficacy and safety of food allergy oral immunotherapy in adults	22
Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma	21
An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata	21
Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases	21
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study	21
Symptom‐based stratification for hay fever: A crowdsourced study using the smartphone application AllerSearch	21
Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST	21
The abundance of Ruminococcus bromii is associated with faecal butyrate levels and atopic dermatitis in infancy	21
Nasal DNA methylation differentiates severe from non‐severe asthma in African‐American children	21
RNA sequencing of single allergen‐specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect	21
Long‐term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS‐CoV‐2 infection	21
Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants	21
Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab‐induced hypereosinophilia	21
Immunoglobulin E response in health and disease beyond allergic disorders	21
SARS‐CoV‐2 candidate vaccines ‐ composition, mechanisms of action and stages of clinical development	20
Comprehending the allergen repertoire of shrimp for precision molecular diagnosis of shrimp allergy	20
FcεRI‐ and MRGPRX2‐evoked acute degranulation responses are fully additive in human skin mast cells	20
BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection, but recognition of mutant viruses is up to 10‐fold reduced	20
The epithelial barrier hypothesis: a 20‐year journey	20